---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-035198"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:51:07.052751+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celldex refutes false report; barzolvolimab PN study continues, Phase 2 subQ planned

## Summary
- Inaccurate report at AAD Annual Meeting stated Celldex terminated Phase 1b barzolvolimab study in prurigo nodularis due to SAE.
- Celldex clarifies study not terminated; DRC unanimously recommended program proceed despite anaphylactic SAE in complicated patient.
- Enrollment closed at 24 patients due to IV administration challenges; blinded study continues with data expected Q4 2023.
- Celldex plans Phase 2 subcutaneous study in PN in late 2023 or early 2024.
- No safety events reported that would meaningfully impact the barzolvolimab development program.

## SEC filing metadata
- accession: 0001104659-23-035198
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465923035198/0001104659-23-035198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465923035198/tm2310208d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-035198
- JSON: https://secwatch.observer/filing/0001104659-23-035198.json
- Plain text: https://secwatch.observer/filing/0001104659-23-035198.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.